Working… Menu
Trial record 9 of 12 for:    "Hyperprolactinemia" | "Tranquilizing Agents"

Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02013232
Recruitment Status : Unknown
Verified December 2013 by Jingxu Chen, Beijing HuiLongGuan Hospital.
Recruitment status was:  Recruiting
First Posted : December 17, 2013
Last Update Posted : December 17, 2013
Information provided by (Responsible Party):
Jingxu Chen, Beijing HuiLongGuan Hospital

Brief Summary:
Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Aripiprazole Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study
Study Start Date : February 2013
Estimated Primary Completion Date : January 2014
Estimated Study Completion Date : February 2014

Arm Intervention/treatment
Placebo Comparator: placebo
risperidone plus placebo
Experimental: aripiprazole 5mg
risperidone treatment plus aripiprazole 5mg/day
Drug: Aripiprazole
Experimental: aripiprazole 10mg
risperidone plus aripiprazole 10mg/day
Drug: Aripiprazole
Experimental: aripiprazole 20mg
risperidone plus aripiprazole 20mg/day
Drug: Aripiprazole

Primary Outcome Measures :
  1. Prolactin level [ Time Frame: baseline, 2 weeks, 4 weeks, 8 weeks ]
    Change from baseline in the levels of prolactin

Secondary Outcome Measures :
  1. PANSS (positive and negative syndrome scale) score [ Time Frame: Baseline, 8 weeks ]
    Change from baseline in PANSS score

Other Outcome Measures:
  1. extrapyramidal symptoms [ Time Frame: baseline, 4 weeks, 8 weeks ]
    assess the extrapyramidal symptoms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. aged 18-45 years of and fulfilled Diagnostic and Statistical Manual of Mental Disorders(DSM-IV )criteria (American Psychiatric Association, 1994) for schizophrenia;
  2. having a stable psychiatric condition, defined as taking the same dosage of risperidone for at least 6 weeks;
  3. being treated with risperidone monotherapy; and presence of hyperprolactinemia associated with risperidone.

Exclusion Criteria:

  1. any other major psychiatric disorder;
  2. significant concurrent medical illnesses, organic brain disorder, history of substance and alcohol abuse, and mental retardation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02013232

Layout table for location contacts
Contact: Jingxu Chen, master 86-13681394260

Layout table for location information
China, Beijing
Beijing HuiLongGuan Hospital Recruiting
Beijing, Beijing, China, 102208
Contact: Jingxu Chen    86-13681394260   
Principal Investigator: Jingxu Chen         
Sponsors and Collaborators
Beijing HuiLongGuan Hospital

Layout table for additonal information
Responsible Party: Jingxu Chen, associate professor, Beijing HuiLongGuan Hospital Identifier: NCT02013232     History of Changes
Other Study ID Numbers: ARI201206
First Posted: December 17, 2013    Key Record Dates
Last Update Posted: December 17, 2013
Last Verified: December 2013
Keywords provided by Jingxu Chen, Beijing HuiLongGuan Hospital:
dose effects
Additional relevant MeSH terms:
Layout table for MeSH terms
Tranquilizing Agents
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Antidepressive Agents
Dopamine Agonists
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Dopamine D2 Receptor Antagonists